Back to top
more

WAVE Life Sciences (WVE)

(Delayed Data from NSDQ)

$5.74 USD

5.74
433,701

-0.06 (-1.03%)

Updated Apr 15, 2024 04:00 PM ET

After-Market: $5.73 -0.01 (-0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for WVE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

WAVE Life Sciences Ltd. [WVE]

Reports for Purchase

Showing records 1 - 20 ( 57 total )

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 1

03/07/2024

Company Report

Pages: 7

Human Genetics Backed INHBE Program is Promising; Reiterate Buy and Raising PT to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 2

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for WVE 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 3

11/10/2023

Company Report

Pages: 7

Part A Data Supportive of the Expectations Surrounding Superior Dystrophin Level Going FORWARD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 4

10/19/2023

Industry Report

Pages: 8

Thematic Takeaways from The ObesityWeek 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 5

09/29/2023

Company Report

Pages: 4

Wave Interferes with Obesity-Our Insights on Inhibin betaE Biology

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 6

08/04/2023

Company Report

Pages: 7

WVE-006 Might Define Wave’s Leadership in RNA Editing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 7

05/24/2023

Daily Note

Pages: 4

C9orf72 A Tough Nut to Crack-Thoughts on FOCUS-C9

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 8

05/04/2023

Company Report

Pages: 7

Sustained Dystrophin Levels with Longer Exposure of WVE-N531 Might be Key; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 9

03/23/2023

Company Report

Pages: 7

Focusing on WVE-N531 With Plans For Harnessing the Power of RNA Medicine; Reit. Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 10

12/20/2022

Daily Note

Pages: 4

WAVE Achieves POC Data in the Clinics¯Thoughts on WVE-N531’s Trial Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 11

12/14/2022

Daily Note

Pages: 4

GSK Eyes On Oligonucleotides Through Wave’s PRISM

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 12

11/11/2022

Company Report

Pages: 7

Thoughts on the Upcoming Data Readout of WVE-N531; Reit. Buy and $8 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 13

09/29/2022

Daily Note

Pages: 4

RNA Editing, An Early But Compelling Approach in AATD¯Initial Thoughts on WVE-006

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 14

09/20/2022

Daily Note

Pages: 4

Wave''s HD Data Encouraging For the PRISM¯Thoughts on the Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 15

08/12/2022

Company Report

Pages: 7

Thoughts on WVE-006¯The Most Advanced ADAR Program Targeting AATD

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 16

05/13/2022

Company Report

Pages: 7

WVE-N531 Update Remains a Central Focus; Reit Buy and Lowering our PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 17

04/05/2022

Daily Note

Pages: 6

WVE-004 Demonstrates Target Engagement in Phase 1 ALS/FTD Study

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 18

03/04/2022

Company Report

Pages: 7

Multiple Shots on Goal Across Diverse CNS Pipeline Define 2022; Reiterate Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 19

11/11/2021

Company Report

Pages: 7

With Steady Progress Across Pipeline, We Choose to Focus on WVE-N531; Reit Buy and $10PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: WAVE Life Sciences Ltd.

Industry: Medical - Biomedical and Genetics

Record: 20

09/29/2021

Daily Note

Pages: 4

Wave Showcases ADAR Potential During R&D Day

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party